Apelix-Piqray’s instructions provide detailed instructions on usage and dosage.
Alpelisib (Alpelisib)-Piqray is a targeted drug used to treat HR-positive, HER2-negative advanced or metastatic breast cancer. According to the instructions, the recommended dosage of Apelvis is 300 mg orally once daily, which is usually achieved by taking two 150 mg film-coated tablets. It is recommended that patients take Apelvis with a meal to help increase the efficiency of absorption of the drug. In terms of daily medication time, try to keep it at the same time, which will help improve patient compliance and treatment effects.

Apelix is generally continued during treatment until disease progression or unacceptable toxicity occurs. In practical applications, doctors will decide whether to continue using or adjust the dose based on the patient's specific situation and tolerance to the drug. Of note, when used in combination with Fulvestrant, the recommended dose of Fulvestrant is 500 mg orally on days 1, 15, and 29, and once a month thereafter. Such a combined treatment plan can enhance the therapeutic effect and improve the patient's survival rate.
In clinical practice, Apelvis may cause some adverse reactions, including but not limited to rash, diarrhea, hyperglycemia, etc. Therefore, doctors may adjust the dose of Apelix based on the patient's constitution and the severity of adverse reactions. For example, if a patient develops significant symptoms of hyperglycemia, doctors may consider lowering the dose of Apelvis or, in some cases, suspending the medication to ensure patient safety.
As with any medication, patients should have regular follow-up visits while taking the medication to monitor effectiveness and side effects. Following your doctor's instructions and regular check-ups will help you identify problems in time and adjust your treatment plan. In addition, while taking Apelvis, patients should pay attention to maintaining a healthy lifestyle, including a reasonable diet and moderate exercise, to improve their overall health and enhance the therapeutic effect.
Reference materials:https://www.piqray.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)